PACS Group, Inc. (PACS) is a Salt Lake City–based post-acute care operator that runs roughly 398 skilled nursing, assisted living, and independent living facilities across 22 states, serving more than 38,000 patients daily. The stock closed Wednesday at $46.30 and was trading at $42.79 shortly before 10:40 a.m. Eastern on Thursday, a decline of 7.58%. The direction is unambiguously negative. No company press release or filing accompanied the move; the decline is best explained by a reimbursement-policy shock radiating through healthcare providers, amplified by governance and insider-selling overhangs specific to PACS.
The dominant force behind Thursday's selling is the regulatory proposal published earlier this week by the Centers for Medicare & Medicaid Services, known as the CRUSH rule. It would expand audits of Medicare, Medicaid, CHIP, and exchange plans, allow the agency to extrapolate sample findings across entire contracts, and claw back improper payments as far back as payment year 2018. CMS estimates roughly $90 billion in taxpayer savings over a decade. For operators whose revenue is overwhelmingly tied to government reimbursement, a stricter audit and recoupment regime is a direct margin risk rather than an abstract compliance cost.
The damage began in managed care, where UnitedHealth (UNH) fell more than 10% on Wednesday, but it spread quickly to facility operators. Post-acute and senior-care names, already pressured by 2027 Medicaid supplemental payment headwinds flagged across the sector, extended losses into Thursday. Senator Bernie Sanders' renewed push for a single-payer program added a second, sentiment-driven layer of anxiety about private reimbursement economics.
PACS is carrying a heavier governance discount than most peers. Insiders have reported roughly $65 million in open-market sales over the trailing 90 days with no offsetting purchases, led by co-founder Mark Hancock and CEO Jason Murray under pre-arranged trading plans. Several law firms have opened inquiries into whether officers and directors breached fiduciary duties, and a securities class action tied to 2024 disclosures remains pending alongside previously disclosed government probes into billing and internal controls. None of this is new, but in a risk-off tape for reimbursement-exposed equities it functions as leverage on the downside.
Positioning explains the magnitude. PACS hit a 52-week high of $51.68 on Nov. 4 after a third-quarter beat — revenue of $1.50 billion, up 11.5%, net income of $60.8 million, and EPS of $0.63 — and had gained more than 30% in a month. It entered Thursday roughly 220% higher over twelve months. With the stock extended and analyst targets clustered at $57 to $67, the policy headline provided a ready excuse to lock in gains.
Roughly 258,000 shares had traded in the first half hour, a pace well ahead of the stock's average daily volume of about 790,000 — evidence of institutional distribution rather than thin, retail-driven slippage. The move was directionally aligned with healthcare facilities broadly but far exceeded it: Brookdale Senior Living (BKD) fell about 2.7%, The Ensign Group (ENSG) about 1.7%, and Universal Health Services (UHS) about 2.8%. PACS broke below its 20-day moving average and sliced through support near $45.50, with the session low of $42.81 marking a 17% retreat from the November peak.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price move. PACS earns 44 out of 100. The verified catalyst is a genuine reimbursement-policy development of real consequence for a company of this size, but it is sector-wide rather than PACS-specific, and no new company disclosure accompanied the session. The price behavior was unusual: at 7.58%, the decline was roughly four times the stock's typical daily move of about 1.9% over the past 60 sessions, and only one session in that window saw a larger absolute swing. A material but second-order catalyst combined with a rare, elevated-volume move produces a mid-range score.
Management presents at the Stephens Annual Investment Conference today, and any commentary on reimbursement exposure, state supplemental payment programs, or 2027 rate assumptions will be parsed closely. Fourth-quarter and full-year 2026 results are expected in late February. Investors will also track the CMS comment period through Jan. 19, 2027, litigation deadlines including a Dec. 7 lead-plaintiff date in related sector litigation, further Form 4 activity, and acquisition integration progress in Texas and Florida. Risks include reimbursement rate compression, elevated leverage, and headline risk from unresolved investigations; supports include a strong buy-side consensus and consistent beat-and-raise execution.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions evolve. Reviewing this page can help investors see which automated approaches are working right now and how they might complement their own research on volatile names like PACS.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PACS declined for three days, in 110 of 147 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
The 10-day RSI Indicator for PACS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 14 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACS as a result. In 29 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for PACS turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In 11 of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
PACS moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for PACS crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +2.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACS advanced for three days, in 110 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
PACS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 96 of 121 cases where PACS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PACS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.073) is normal, around the industry mean (204.532). P/E Ratio (28.837) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.085) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (1.209) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement